Evidence map›Paper›PMID 40185900›Full record

ArticleMolecular psychiatry2025

Impaired synaptosome phagocytosis in macrophages of individuals with autism spectrum disorder.

Yuki Nishi, Michihiro Toritsuka, Ryohei Takada, Mitsuru Ishikawa, Rio Ishida, Yoshinori Kayashima, Takahira Yamauchi, Kazuki Okumura, Tsutomu Takeda, Kazuhiko Yamamuro and 9 more

Abstract read
In one paragraph

Article in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yuki Nishi *Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Michihiro Toritsuka *Department of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan. michihiro.toritsuka@fujita-hu.ac.jp.ORCID 0000-0001-6891-4173
Ryohei TakadaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Mitsuru IshikawaDepartment of Physiology, Keio University School of Medicine, Shinjuku-ku, Tokyo, 160-8582, Japan.
Rio IshidaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Yoshinori KayashimaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Takahira YamauchiDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Kazuki OkumuraDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.ORCID 0000-0002-3019-7049
Tsutomu TakedaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Kazuhiko YamamuroDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.ORCID 0000-0002-4362-3262
Minobu IkeharaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Yuki NoriyamaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Kohei KamikawaDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan.
Shuhei MurayamaResearch and Development, Sumitomo Pharma Co., Ltd., Osaka city, Osaka, 554-0022, Japan.
Osamu IchikawaResearch and Development, Sumitomo Pharma Co., Ltd., Osaka city, Osaka, 554-0022, Japan.
Hidetaka NagataResearch and Development, Sumitomo Pharma Co., Ltd., Osaka city, Osaka, 554-0022, Japan.ORCID 0000-0003-4109-7657
Hideyuki OkanoDivision of CNS Regeneration and Drug Discovery, International Center for Brain Science (ICBS), Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.ORCID 0000-0001-7482-5935
Nakao IwataDepartment of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470-1192, Japan.ORCID 0000-0003-3189-6076
Manabu MakinodanDepartment of Psychiatry, Nara Medical University School of Medicine, Kashihara, Nara, 634-8522, Japan. manabu.makinodan@fujita-hu.ac.jp.

Funding

Japan Agency for Medical Research and Development (AMED) 21wm04250XXs0101, 21uk1024002h0002, 21gm6310015h0002, 22gm1510009h0001, 23gm1910004s0301Japan Agency for Medical Research and Development (AMED) 22bm0804023h0003
6 · The paper itself

Abstract

Dendritic spine abnormalities are believed to be one of the critical etiologies of autism spectrum disorder (ASD). Over the past decade, the importance of microglia in brain development, particularly in synaptic elimination, has become evident. Thus, microglial abnormalities may lead to synaptic dysfunction, which may underlie the pathogenesis of ASD. Several human studies have demonstrated aberrant microglial activation in the brains of individuals with ASD, and studies in animal models of ASD have also shown a relationship between microglial dysfunction and synaptic abnormalities. However, there are very few methods available to directly assess whether phagocytosis by human microglia is abnormal. Microglia are tissue-resident macrophages with phenotypic similarities to monocyte-derived macrophages, both of which consistently exhibit pathological phenotypes in individuals with ASD. Therefore, in this study, we examined the phagocytosis capacity of human macrophages derived from peripheral blood monocytes. These macrophages were polarized into two types: those induced by granulocyte-macrophage colony-stimulating factor (GM-CSF MΦ, traditionally referred to as "M1 MΦ") and those induced by macrophage colony-stimulating factor (M-CSF MΦ, traditionally referred to as "M2 MΦ"). Synaptosomes purified from human induced pluripotent stem cell-derived neuron were used to assess phagocytosis capacity. Our results revealed that M-CSF MΦ exhibited higher phagocytosis capacity compared to GM-CSF MΦ, whereas ASD-M-CSF MΦ showed a marked impairment in phagocytosis. Additionally, we found a positive correlation between phagocytosis capacity and cluster of differentiation 209 expression. This research contributes to a deeper understanding of the pathobiology of ASD and offers new insights into potential therapeutic targets for the disorder.

Indexed as

Autism Spectrum DisorderMacrophagesPhagocytosisSynaptosomesBrainFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansInduced Pluripotent Stem CellsMacrophage Colony-Stimulating FactorMaleMicrogliaMonocytesNeuronsGranulocyte-Macrophage Colony-Stimulating FactorMacrophage Colony-Stimulating Factor

Identifiers

PMID40185900
PMCPMC12240830

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.